KRAS and non-small cell lung carcinoma: Collectively, these results suggest that hyper-activation of JNK signaling in the absence of LKB1 increases the MCL-1 dependence of LKB1-deficient KRAS-mutant NSCLC cells and sensitizes them to combined KRASG12C or MEK + MCL-1 inhibition.